const supriya = [
  {
    text: 'Introduction',
    card: `    <div className="fs-25">
        <p className="mt-3">
          Incorporated as Supriya Lifescience Limited in 2008 M/s Supriya
          Chemicals, a partnership concern, was converted into a public limited
          company and is now involved in the production and export of active
          medicinal ingredients (APIs). It is a major manufacturer and supplier of
          active pharmaceutical ingredients in India, with a concentration on
          research and development. As of 2021, the company's specialty product
          offerings consisted of 39 APIs focusing on various therapeutic
          categories such as antihistamine, analgesic, anaesthetic, vitamin,
          anti-asthmatic, and antiallergic.
        </p>
  
        <p className="mt-3">
          Spread across an area of 47,000 sq.m. with delineated areas for
          warehouse, QA, QC, R &amp; D, company’s facility supports production and
          finished products (dedicated blocks for different therapeutic segments).
          The plant has current capacity of 550 KL and supported with multiple
          clean rooms for finished products.
        </p>
  
        <p className="mt-3">
          <strong>
            As a part of capacity expansion plan, company’s capacity would be
            approximately 1000+ KL by 2024 as said by the management.
          </strong>
        </p>
  
        <p className="mt-3">
          Between Fiscal 2017 and 2020, the company was consistently one of the
          largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride
          from India, accounting for 45-55% and 65-70%, respectively, of India's
          API exports.
        </p>
  
        <p className="mt-3">
          <em>
            <strong>Chlorpheniramine Maleate</strong> is&nbsp;
            <strong>an antiallergic medication.</strong>
            Chlorpheniramine&nbsp;relieves red, itchy, watery eyes; sneezing;
            itchy nose or throat; and runny nose caused by allergies, hay fever,
            and the common cold. Chlorpheniramine helps control the symptoms of
            cold or allergies but will not treat the cause of the symptoms or
            speed recovery.
          </em>
        </p>
  
        <p className="mt-3">
          <em>
            <strong>Ketamine Hydrochloride</strong> belongs to a class of drugs
            called General Anesthetics, Systemic. Ketamine Hydrochloride is a
            prescription medicine used as a&nbsp;
            <a href="https://www.rxlist.com/sedative/definition.htm">sedative</a>
            &nbsp;for diagnostic and surgical procedures. Ketamine Hydrochloride
            may be used alone or with other medications.
          </em>
        </p>
  
        <p className="mt-3">
          The company was among the largest exporters of Salbutamol Sulphate from
          India in Fiscal 2020 in terms of volume.
        </p>
  
        <p className="mt-3">
          <em>
            <strong>Salbutamol</strong> is used&nbsp;to rapidly treat asthma,
            bronchospasm and reversible airways obstruction by widening the
            airways of the lungs.
          </em>
        </p>
  
        <p className="mt-3">
          The company's products are approved by various international regulatory
          authorities such as USFDA, EUGMP, EDQM, SFDA NMPA, ANVISA, KFDA, PMDA,
          TGA and Taiwan FDA.
        </p>
  
        <p className="mt-3">
          As of 2021, the company have filed 11 active DMFs with USFDA and seven
          active CEPs with EDQM, for API products in therapeutic areas such as
          antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and
          anti-allergic.
        </p>
      </div> `,
  },
  {
    text: 'Business Products',
    card: `    <div className="fs-25">
        <div className="d-flex mt-3 w-100 justify-content-between">
          <img
            src="https://darkhorsestocks.com/wp-content/uploads/2022/12/Finance1-1024x725.png"
            alt=""
            className="w-40"
            height="250"
          />
          <img
            src="https://darkhorsestocks.com/wp-content/uploads/2022/12/Finance2-1024x626.png"
            alt=""
            className="w-40"
            height="250"
          />
        </div>
  
        <p className="mt-3">
          Antihistamines are&nbsp;
          <strong>
            medicines often used to relieve symptoms of allergies, such as hay
            fever, hives, conjunctivitis and reactions to insect bites or stings
          </strong>
          . They're also sometimes used to prevent motion sickness and as a
          short-term treatment for insomnia.
        </p>
  
        <h3 className="mt-3">
          <strong>Analgesic / Anti-Pyretic / Anesthetic</strong>
        </h3>
  
        <p className="mt-3">
          Analgesics are a class of medications designed specifically to&nbsp;
          <strong>relieve pain</strong>. They include acetaminophen (Tylenol),
          which is available over the counter (OTC) or by prescription when
          combined with another drug, and opioids (narcotics), which are only
          available by prescription.
        </p>
  
        <h3 className="mt-3">
          <strong>Anti-Allergic</strong>
        </h3>
  
        <p className="mt-3">
          Antihistamines are&nbsp;
          <strong>
            medicines that treat allergy symptoms by blocking the effects of
            histamine
          </strong>
          . Antihistamines come as pills, chewable tablets, capsules, liquids,
          nasal sprays, and eye drops. There are also injectable forms used mainly
          in health care settings.
        </p>
  
        <h3 className="mt-3">
          <strong>Anti-Asthmatic</strong>
        </h3>
  
        <p className="mt-3">
          An antiasthmatic and antiallergic agent that prevents mast cell release
          of histamine and formation of other mediators (leukotrienes) of
          anaphylaxis by inhibiting degranulation after contact with antigens.
          Treatment of allergic rhinitis, severe perennial bronchial asthma,
          exercise-induced bronchospasm (prevention), prevention of acute
          bronchospasm induced by environmental pollutants, mastocytosis
        </p>
  
        <h3 className="mt-3">
          <strong>Vitamin</strong>
        </h3>
  
        <p className="mt-3">
          This medication is a multivitamin product used&nbsp;
          <strong>
            to treat or prevent vitamin deficiency due to poor diet, certain
            illnesses, or during pregnancy
          </strong>
          . Vitamins are important building blocks of the body and help keep you
          in good health.
        </p>
  
        <h3 className="mt-3">
          <strong>Anti-Hypertensive</strong>
        </h3>
  
        <p className="mt-3">
          <strong>A type of drug used to treat high blood pressure</strong>. There
          are many different types of antihypertensive agents, and they work in
          different ways to lower blood pressure. Some remove extra fluid and salt
          from the body. Others relax and widen the blood vessels or slow the
          heartbeat.
        </p>
      </div>`,
  },
  {
    text: 'Products in pipeline',
    card: `    <div className="fs-25">
        <table className="table mt-3">
          <thead>
            <tr>
              <th>
                <strong>API’s Under Pipeline</strong>
              </th>
              <th></th>
              <th>
                <strong>Status</strong>
              </th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>
                <strong>USDMF’s</strong>
              </td>
              <td>
                Microsoft Word - Cov Letter
                <br />
                <strong>15 API’s</strong>
              </td>
              <td>
                <strong>Submitted</strong>
              </td>
            </tr>
            <tr>
              <td>
                <strong>CEP</strong>
              </td>
              <td>
                <strong>9 API’s</strong>
              </td>
              <td>
                <strong>Granted</strong>
              </td>
            </tr>
            <tr>
              <td>
                <strong>USDMF</strong>
              </td>
              <td>
                <strong>4 API</strong>
              </td>
              <td>
                <strong>Submission Under Progress</strong>
              </td>
            </tr>
            <tr>
              <td>
                <strong>CEP</strong>
              </td>
              <td>
                <strong>1 API’s</strong>
              </td>
              <td>
                <strong>Assessment Under Progress</strong>
              </td>
            </tr>
            <tr>
              <td>
                <strong>CEP</strong>
              </td>
              <td>
                <strong>4 API’s</strong>
              </td>
              <td>
                <strong>Submission Under Progress</strong>
              </td>
            </tr>
            <tr>
              <td></td>
              <td></td>
              <td></td>
            </tr>
            <tr>
              <td></td>
              <td></td>
              <td></td>
            </tr>
            <tr>
              <td></td>
              <td></td>
              <td></td>
            </tr>
          </tbody>
        </table>
      </div> `,
  },
  {
    text: 'Certificates',
    card: `<div className="fs-25">
        <img
          src="https://darkhorsestocks.com/wp-content/uploads/2022/12/Certifices-1024x472.png"
          alt=""
          class="w-100 mt-3"
        />
      </div> `,
  },
  {
    text: 'Financials',
    card: `     <div className="fs-25 mt-3">
        <img
          src="https://darkhorsestocks.com/wp-content/uploads/2022/12/Finance8-1024x722.png"
          alt=""
          class="w-100"
        />
        <div className="d-flex w-100 justify-content-between mt-1">
          <img
            src="https://darkhorsestocks.com/wp-content/uploads/2022/12/Finance4-1024x724.png"
            alt=""
            className="w-40"
          />
          <img
            src="https://darkhorsestocks.com/wp-content/uploads/2022/12/Finance5-1024x720.png"
            alt=""
            className="w-40"
          />
        </div>
        <div className="d-flex w-100 justify-content-between mt-1">
          <img
            src="https://darkhorsestocks.com/wp-content/uploads/2022/12/Finance6-1024x724.png"
            alt=""
            className="w-40"
          />
          <img
            src="https://darkhorsestocks.com/wp-content/uploads/2022/12/Finance7-1024x724.png"
            alt=""
            className="w-40"
          />
        </div>
  
        <h3 className="mt-3">For the year ended March 2022</h3>
  
        <ul className="mt-2 list-items">
          <li>
            Revenues from operations increased to 35.50% from Rs 391 cr in 2020-21
            to Rs 530 cr in 2021-2.
          </li>
  
          <li>
            The capital employed by the Company increased 112% from Rs 299.45 cr
            as on March 31, 2021 to Rs 635.06 cr as on March 31, 2022
          </li>
  
          <li>
            The net worth of the Company increased by 129% from Rs 268.58 cr as on
            March 31, 2021 to Rs 615.69 cr as on March 31, 2022
          </li>
  
          <li>
            The Company’s net debt / equity ratio stood at a comfortable 0.04x at
            the close of 2021-22.
          </li>
  
          <li>
            The EBITDA margin of the Company for 2020-21 was 46% as against 42% in
            2021-22 while the net profit for 2020-21 was 31% as against 28% in
            2021-22.
          </li>
  
          <li>
            Profit before Tax (PBT) for the year has grown by 24% to Rs 2072.45
            million as against a PBT of Rs 1673.09 million for the last year.
          </li>
  
          <li>
            Profit after Tax (PAT) before other comprehensive income for the year
            grew by 23% to Rs 1518.10 million as against a PAT of Rs 1235.93
            million last year.
          </li>
  
          <li>
            Cash and bank balance was Rs. 190 crores out of which Rs. 180 crores
            was in fixed deposits.
          </li>
        </ul>
  
        <h3 className="mt-3">
          <strong>For Q2 FY 23</strong>
        </h3>
  
        <ul className="mt-2 list-items">
          <li>
            Net Sales stood at Rs 112.17 crore in September 2022 down 24.21% from
            Rs. 148.01 crore in September 2021.
          </li>
  
          <li>
            Quarterly Net Profit stood at Rs. 16.86 crore in September 2022 down
            71.04% from Rs. 58.22 crore in September 2021.
          </li>
  
          <li>
            EBITDA stood at Rs. 54.14 crore in September 2022 down 33.38% from Rs.
            81.27 crore in September 2021.
          </li>
  
          <li>
            Supriya Lifesci EPS has decreased to Rs. 2.10 in September 2022 from
            Rs. 7.96 in September 2021.
          </li>
        </ul>
      </div>`,
  },

  {
    text: 'Capex',
    card: `    <div className="fs-25 ">
        <img
          src="https://darkhorsestocks.com/wp-content/uploads/2022/12/Finance3-1024x723.png"
          alt=""
          class="w-100 mt-3"
        />
  
        <ul className="mt-2 list-items">
          <li>
            Supriya is actively improving its infrastructure at the Lote Parshuram
            location (three times authorised by the USFDA) to construct an R&amp;D
            centre, warehouse, administrative, and effluent treatment facilities.
          </li>
  
          <li>
            The company started replacing its old production block with a 350 kl
            capacity with a 350 kl successor (with a provision for an additional
            manufacturing block). Ambernath is getting a new manufacturing block,
            R&amp;D facility, and pilot plant. These projects have the potential
            to increase total capacity from 547 KL to around 810 KL.
          </li>
  
          <li>
            Work on construction of E block with about 350 KL reactor capacity is
            in progress. A new manufacturing block with a capacity of 70 KL
            attached to the new R&amp;D facility with pilot plant is being set up
            at Ambernath.
          </li>
  
          <li>
            The company leased 80,000 square metres from Maharashtra Industrial
            Development Corporation (MIDC) in Isambe Industrial Park to produce
            pharmaceutical ingredients and medication intermediates. The present
            production facilities are scheduled to be completely utilised by
            2024-25, after which the additional MIDC allocation might satisfy
            future needs.
          </li>
  
          <li>
            So far company has made capex of about 127 crs in last 4 years and
            plans to do additional 100 crs till 2024-2025.
          </li>
  
          <li>
            Key focus area will be to increase presence in regulatory market with
            new emerging market, backward integration, optimization of
            manufacturing capacity with proper utilization of man, material and
            machinery**,** ZLF upgradation, in-house ZLD and automation.
          </li>
        </ul>
      </div> `,
  },
  {
    text: 'Sectorial Outlook',
    card: `    <div className="fs-25 ">
        <p className="mt-3">
          The worldwide active pharmaceutical ingredients market is expected to
          increase at a 6.9% CAGR from USD 208.9 million in 2021 to USD 334
          million by 2028.
        </p>
  
        <p className="mt-3">
          North America has the biggest market share for active pharmaceutical
          ingredients, followed by Europe and Asia Pacific.
        </p>
  
        <p className="mt-3">
          In 2021, the active pharmaceutical ingredients (API) industry in the
          United States is expected to be worth USD 71.5 billion. At the moment,
          the country accounts for 36.3% of the global market. The Chinese active
          pharmaceutical ingredients (API) market is predicted to develop at a
          7.6% CAGR to USD 35.4 billion by 2026.
        </p>
  
        <p className="mt-3">
          Other key regional markets, such as Japan and Canada, are predicted to
          increase by 6.1% and 6.5%, respectively, between 2021 and 2026.
          Germany's market share in Europe is predicted to grow at a 6.1% CAGR,
          while the rest of Europe's market will reach USD 37.5 billion by 2026.
        </p>
  
        <p className="mt-3">
          China, as a significant producer and exporter of APIs, accounts for
          around 20% of global API output.
        </p>
  
        <p className="mt-3">
          The Indian active pharmaceutical ingredients market was worth USD 11.8
          billion in 2020-21 and is expected to increase at a 12.24% CAGR until
          2026-27.
        </p>
  
        <p className="mt-3">
          Compared to 2020 the investment in the API business has expanded by 3X
          in 2021. The country’s API industry is on a growing trajectory. It meets
          over 20% of the worldwide generics market's volume demand, making India
          the world's largest provider of generic medications.
        </p>
      </div> `,
  },
  {
    text: '',
    card: ` `,
  },
  {
    text: '',
    card: ` `,
  },
  {
    text: '',
    card: ` `,
  },
  {
    text: '',
    card: ` `,
  },
  {
    text: '',
    card: ` `,
  },
  {
    text: '',
    card: ` `,
  },
  {
    text: '',
    card: ` `,
  },
  {
    text: '',
    card: ` `,
  },
];
